$2.04 (2.26%)

Volume: 6.651k

Closed: Mar 28, 2023

Hollow Logo Score: -3.305
Cellectis S.A. Stock
$2.04 (2.26%)

Volume: 6.651k

Closed: Mar 28, 2023

Score Hollow Logo -3.305
NASDAQ:CLLS

Cellectis S.A. Stock Predictions

Currently predicting for Thu, 30 Mar 2023

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 2.08 2.13 %
R2 2.06 1.38 %
R1 2.05 0.91 %
Current price: 2.04
Support S1 2.02 -0.587 %
S2 2.01 -1.05 %
S3 2.00 -1.80 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 2.51 23.34 %
R2 2.38 16.95 %
R1 2.25 10.57 %
Current price 2.04
Support S1 1.99 -2.21%
S2 1.95 -4.18%
S3 1.90 -6.88%

CLLS Predictions History

3 years ago
GoldenNugget predicted that CLLS for 2019-05-07 is going $20.11 (-1.28%)

3 years ago
GoldenNugget predicted that CLLS for 2019-05-06 is going $19.89 (-0.56%)

5 years ago
JS predicted that CLLS for 2017-05-08 is going $24.57 (3.32%)

5 years ago
ftc predicted that CLLS for 2017-05-08 is going $19.22 (-22.75%)

Rank:
Click to get the best stock tips daily for free!

About Cellectis S.A.

Cellectis SA Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALL... CLLS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT